JNCI Cancer Spectrum最新文献

{"title":"Engaging community oncology stakeholders to plan multisite cancer caregiving research (CONNECT WF-2300CD).","authors":"Sarah S Asad, Beverly J Levine, Anna C Snavely, Kathryn E Weaver, Michael K Farris, Sarah N Price, Melyssa Foust, Kristi D Graves, Chad Dingman, Martha S Tingen, Jenni Danai, Jessica Sheedy, Bonny Morris, Chandylen Nightingale","doi":"10.1093/jncics/pkag065","DOIUrl":"10.1093/jncics/pkag065","url":null,"abstract":"<p><strong>Background: </strong>Engaging community stakeholders in clinical trials planning identifies participation barriers and facilitators to support future trial success. We assessed interest and perceived capacity of the National Cancer Institute Community Oncology Research Program (NCORP) practices and engaged stakeholders to inform a future multisite clinical trial involving caregivers.</p><p><strong>Methods: </strong>A cross-sectional survey of NCORP practices (WF-2300CD) assessed interest (somewhat or very likely to participate) and capacity (ie, criteria: ≥5 eligible dyad accruals per quarter, identification of necessary study implementers) and barriers and facilitators to participating in a future cancer caregiver-focused trial. Interest and capacity were estimated with 95% confidence intervals (CIs), and logistic regression was used to identify statistically significant predictors. Free-text responses were analyzed using content analysis.</p><p><strong>Results: </strong>Among 136 initial responding practices, 126 (92%) completed the survey (November 2023-April 2024), 56% saw at least 1000 new patient cases annually, 13.5% served at least 30% racial and ethnic minority patients, and 13.5% were designated critical access hospitals. Overall, 84.9% (95% CI = 77.5% to 90.1%) expressed interest in a caregiver-focused trial, but only 37.3% (95% CI = 28.9% to 46.4%) met all capacity criteria; capacity was the sole predictor of interest (adjusted odds ratio [OR] = 5.79, 95% CI = 1.23 to 27.13). Most (88.9%) practices estimated 5 or more eligible caregiver-patient dyads per quarter, but only 44.4% believed they could accrue that amount. Key participation barriers included staffing limitations and challenges related to eligibility and recruitment. Practices emphasized clear guidance on dyad eligibility, recruitment materials, workflow training, and resource considerations to improve trial participation.</p><p><strong>Conclusion: </strong>Early stakeholder engagement identified actionable barriers and produced practice-aligned strategies to enhance caregiver trial participation in community oncology settings. Targeted capacity building may improve participation for future caregiver-focused trials.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13385343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of body mass index and circulating metabolic factors as predictors of metformin benefit in the Canadian Cancer Trials Group MA.32.","authors":"Pamela J Goodwin, Marguerite Ennis, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Jennifer A Ligibel, Alastair M Thompson, Lois E Shepherd, Wendy R Parulekar, Ryan Dowling, Vuk Stambolic","doi":"10.1093/jncics/pkag045","DOIUrl":"10.1093/jncics/pkag045","url":null,"abstract":"<p><strong>Background: </strong>In the MA.32 randomized adjuvant breast cancer trial, metformin (vs placebo) did not impact invasive disease-free survival or overall survival in estrogen and/or progesterone receptor-positive or -negative breast cancer; exploratory analyses suggested a benefit in HER2-positive breast cancer. We investigated whether body mass index (BMI) and obesity-associated blood variables predicted metformin benefit in immunohistochemically defined breast cancer subtypes (luminal [estrogen/progesterone receptor positive, HER2 negative], triple-negative breast cancer [estrogen receptor, progesterone receptor, HER2 negative], HER2 positive).</p><p><strong>Methods: </strong>A total of 3649 nondiabetic patients with high risk T1-3, N0-3, M0 breast cancer were randomly assigned. Baseline fasting plasma was assayed for insulin, glucose, leptin, and C-reactive protein; Homeostasis Model Assessment was calculated. For each breast cancer subtype and each outcome (distant recurrence free survival, overall survival, invasive disease-free survival), Cox models examined interactions of BMI and blood variables with metformin vs placebo outcomes.</p><p><strong>Results: </strong>Mean age was 51.1-53.0 years; mean BMI was 27.3-27.5 kg/m2. Most cancers were T2, N0, or N1 and grade 2-3; 2104 (57.7%) were luminal, 925 (25.3%) TN, and 620 (17.0%) HER2 positive. Median follow-up was 95.9 months. In luminal breast cancer, statistically significant interactions were identified for leptin, insulin, and Homeostasis Model Assessment on distant recurrence-free survival, and in triple-negative breast cancer, a statistically significant interaction was identified for glucose on distant recurrence-free survival, with potential adverse effects of metformin at lower levels of each variable. In those with HER2-positive breast cancer, there was no variable that predicted metformin benefit.</p><p><strong>Conclusions: </strong>Body mass index and blood variables did not identify subgroups with luminal or triple-negative breast cancer who benefited from metformin or those with HER2-positive breast cancer who did not benefit.</p><p><strong>Clinical trial registration number: </strong>ClinicalTrials.gov NCT01101438: 2010-04-09.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13456960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes in pediatric acute lymphoblastic leukemia using modified BFM-95 protocol: 10-year study in Mexico City.","authors":"Karina A Solis-Labastida, Rosa E Valdez-Avilez, Salvador Atilano-Miguel, Jorge A Martin-Trejo, Lourdes Barbosa-Cortés, Benito A Bautista-Martínez, Azalia Juárez-Moya, Zayra Hernández-Piñón","doi":"10.1093/jncics/pkag061","DOIUrl":"10.1093/jncics/pkag061","url":null,"abstract":"<p><strong>Background: </strong>Although survival rates for acute lymphoblastic leukemia (ALL) in developed countries have reached up to 80%, outcomes remain considerably lower in emerging nations. This study aimed to evaluate the 10-year survival of pediatric patients with ALL treated at a public hospital using the HP 09 protocol, adapted from the BFM 95 protocol.</p><p><strong>Methods: </strong>We included patients under 17 years of age diagnosed with ALL and treated with the HP 09 protocol between January 2010 and December 2020. Patients were stratified into 3 risk groups according to clinicobiological characteristics.</p><p><strong>Results: </strong>A total of 253 patients were analyzed. The cohort demonstrated a 10-year overall survival (OS) rate of 58.1% (90.4 ± 4.8 months) and an event-free survival (EFS) rate of 56.9% (78.2 ± 5.0 months). By risk group, the 10-year OS was 41% in the high-risk group, 61.9% in the intermediate-risk group, and 85.7% in the standard-risk group. Corresponding 10-year EFS rates were 55.2%, 57.1%, and 59.7%. Cox regression analysis identified older age (>10 years; OR = 2.11, 95% CI = 1.36 to 3, P = .001), leukocyte count >50 × 109/L (OR = 1.89, 95% CI = 1.22 to 2.93, P = .004), and prior steroid exposure before diagnosis (OR = 2.30, 95% CI = 1.16 to 4.58, P = .017) as significant predictors of relapse.</p><p><strong>Conclusions: </strong>This study highlights a substantial disparity in survival rates among pediatric patients with ALL in Mexico compared with international benchmarks. The gap likely reflects differences in chemotherapy efficacy, disease biology, and systemic healthcare limitations.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148251537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between author specialty and reported outcomes in non-randomized comparisons of prostatectomy versus radiation.","authors":"Zakaria El Kouzi, Mohammed A Mohammed, Michael Kevin Rooney, Ramez Kouzy, Jie Jane Chen, Shalin Shah, Tarek Al Bitar, Sherif M Gadoue, Comron Hassanzadeh, Steven Frank, Phuoc Tho Tran, Chad Tang, Seungtaek Choi, Ryan Jin-Hyung Park, Karen Hoffman, Sean Eric McGuire, Henry Mok, Quynh-Nhu Nguyen, Adam B Samman, Zain Rahman, Mohamed Shelan, Toufic Eid, Osama Mohamad","doi":"10.1093/jncics/pkag069","DOIUrl":"10.1093/jncics/pkag069","url":null,"abstract":"<p><strong>Background: </strong>While the ProtecT randomized trial demonstrated comparable oncologic outcomes between radical prostatectomy (RP) and radiation therapy (RT) for localized prostate cancer, several retrospective studies have reported mixed findings. In this study, we investigated whether non-randomized studies tend to favor RP or RT and assessed whether the specialty of leading authors-urologists or radiation oncologists-correlates with study conclusions.</p><p><strong>Methods: </strong>We identified non-randomized clinical studies published between 1993 and 2024 that compared RP and RT for localized prostate cancer and reported oncologic outcomes including biochemical, metastasis, and/or survival outcomes. Author specialty was determined based on whether the first and senior authors were affiliated with urology or radiation oncology departments. Studies in which a urologist and radiation oncologist were first and senior authors were excluded. Each study's conclusion was categorized as favoring surgery, favoring radiation, or reporting no conclusive difference in oncologic outcomes. Multivariate logistic regression was used to evaluate predictors of study conclusions.</p><p><strong>Results: </strong>A total of 105 studies met inclusion criteria. Nearly half (44%) reported no conclusive difference in outcomes, while 42% favored RP and 14% favored RT. Multivariate analysis showed that use of national databases (P = .01) and urology author specialty (P = .01) predicted conclusions aligning with the author's specialty. In a subgroup excluding studies relying solely on biochemical recurrence-free survival outcomes, author specialty remained associated with conclusions, with urologists more likely to favor RP (P = .006).</p><p><strong>Conclusion: </strong>Author specialty was associated with the direction of study conclusions. Further research is needed to understand how these patterns may influence interpretation and decision-making in prostate cancer treatment.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13394490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148368588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Bates.","authors":"Gabriel A Benavidez, Ami E Sedani, Tisha M Felder, Matthew Asare, Charles R Rogers","doi":"10.1093/jncics/pkag064","DOIUrl":"10.1093/jncics/pkag064","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV infection and survival in Hodgkin lymphoma: a real-world analysis of a multicenter research network.","authors":"Shih-Ping Lin, Tsung-Han Yen, Jian-Ri Li, Cheng-Wei Chou","doi":"10.1093/jncics/pkag076","DOIUrl":"10.1093/jncics/pkag076","url":null,"abstract":"<p><strong>Background: </strong>Despite effective antiretroviral therapy, people living with human immunodeficiency virus (HIV) (PLWH) remain at a higher risk of developing Hodgkin lymphoma (HL). Further, survival disparities persist despite similar treatment recommendations.</p><p><strong>Methods: </strong>Herein, we present a global retrospective cohort study including data of adults (≥18 years) diagnosed with HL between 2015 and 2025 from the TriNetX database to evaluate the survival outcomes of Hodgkin lymphoma in HIV-infected vs non-HIV-infected patients and analyze the associated risk factors. Patients were stratified according to HIV status and matched 1:1 for age, sex, race, and comorbidities. Overall survival (OS) was analyzed using Kaplan-Meier and Cox proportional hazards models.</p><p><strong>Results: </strong>A total of 927 matched HIV-infected and non-HIV-infected patients were included. Overall, HIV-positive status was associated with significantly inferior OS (HR 1.42; 95% CI 1.10-1.84; P = .033). Among PLWH, cerebrovascular disease, hepatitis C virus infection, and chronic kidney disease independently predicted increased mortality. In a matched subgroup of patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy (n = 154 per group), OS did not differ significantly between the HIV-positive and HIV-negative groups (HR 1.37; 95% CI 0.73-2.56; P = .247).</p><p><strong>Conclusion: </strong>In conclusion, HIV-infected patients with HL experienced worse OS compared with non-HIV-infected individuals, but the outcomes were comparable when treated with ABVD chemotherapy, highlighting the importance of optimal treatment delivery and comorbidity management in PLWH.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in adult exclusive and dual use of combustible and non-combustible tobacco products in the United States.","authors":"Kenneth Michael Cummings, Avery Roberson, Colin W Randol, Tracy T Smith, David T Levy, Yoonseo Mok, Steve Cook, Rafael Meza","doi":"10.1093/jncics/pkag062","DOIUrl":"10.1093/jncics/pkag062","url":null,"abstract":"<p><strong>Background: </strong>As tobacco use patterns shift toward non-combustible tobacco products such as electronic cigarettes (ECs) and nicotine pouches, dual use with combustible products may undermine potential public health benefits. Herein we describe adult trends in exclusive and dual use of combustible and non-combustible products in the United States between 2015 and 2023.</p><p><strong>Methods: </strong>We analyzed annual National Health and Interview Survey data including all adults with valid data on tobacco use, age, and sex. Joinpoint regression estimated annual percentage change (APC) and 95% CIs overall and by age group and sex. All tests were 2-tailed (P < .05).</p><p><strong>Results: </strong>Exclusive combustible use remained 2-3 times higher than exclusive non-combustible use or dual use across all years. From 2015 and 2023, combustible use declined in both sexes, with the steepest drops in younger adults after 2020. Exclusive non-combustible use increased in all age groups after 2017, especially among younger adults and females. The most common dual use pattern was cigarettes plus ECs, which was stable over time.</p><p><strong>Conclusions: </strong>Exclusive use of combustible tobacco, primarily cigarettes, is declining but remains the most common pattern, especially in older adults. In contrast, exclusive EC use is displacing combustible use among younger adults. Dual use patterns were low overall and stable across the study period.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":"10 4","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13402021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Rural-urban disparities and trends in cancer screening: an analysis of Behavioral Risk Factor Surveillance System data (2018-2022).","authors":"Neill Bates","doi":"10.1093/jncics/pkag063","DOIUrl":"10.1093/jncics/pkag063","url":null,"abstract":"","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13387159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-based multimodal multitask analysis of thyroid ultrasound image features predicts thyroid cancer: a multicenter study.","authors":"Yu Gui, Xuerui Zhang, Yun He, Tingting Li, Lan Hu, Longle Liu, Dan Peng, Juan Yuan, Xiaoyu Xiong, Wenhan Li, Xin Wu, Shichao Li, Haiyan Fan, Tijie Peng, Xi Yang, Xiang Cui, Ying Yang, Lingjuan Zeng, Dajiang Song, Feng Liu, Jianhui Li, Peng Wang, Zhongquan Huang, Li Chen","doi":"10.1093/jncics/pkag037","DOIUrl":"10.1093/jncics/pkag037","url":null,"abstract":"<p><strong>Background: </strong>Thyroid nodule ultrasound (US) images and their features are of great importance in thyroid nodule diagnosis and can be helpful for radiologists' clinical decision making. The aim was to evaluate whether an artificial intelligence (AI)-assisted system can accurately characterize thyroid nodule US features and assist radiologists in diagnosing thyroid cancer.</p><p><strong>Methods: </strong>The AI-assisted system (MDT-TC) was trained and internally validated on B-mode US images from 7204 lesions in 6884 patients in Southwest Hospital. The model performance was validated using 3 independent external validation cohorts.</p><p><strong>Results: </strong>Echogenicity (ECH) and shape (SHA) are features of high importance for model recognition, and these features lead to excellent model performance. The model achieved up to 87.56% accuracy in determining ECH attributes and 69.21% in identifying shape categories. The area under the receiver operating characteristic curve (AUC) of the internal validation cohort and 3 independent external validation cohorts for MDT-TC were 0.951, 0.837, 0.816, and 0.871, respectively. The sensitivity values were 98.7%, 91.2%, 90.3%, and 85.6%, respectively. The AUC for the accurate diagnosis of radiologists with MDT-TC assistance was significantly higher than that of radiologists without MDT-TC assistance (P < .001). In addition, the AUC for the accurate diagnosis of junior doctors with MDT-TC assistance was significantly higher than that for those without (P < .01).</p><p><strong>Conclusion: </strong>MDT-TC incorporates radiomic features extracted from thyroid lesion US images and can significantly improve the diagnostic performance of radiologists. This result was particularly strong for junior doctors. Therefore, our data support the idea that MDT-TC can help to identify patients with thyroid cancer and could greatly benefit clinical practice.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13341012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147673510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study of the Hopetimize program for pediatric oncology healthcare professionals.","authors":"Chelsea S Rapoport, Benjamin W Corn, Phyllis Dvora Corn, Alyssa K Choi, Shea O'Donnell, Michal Manasseh, Vanessa L Malcarne, Dennis J Kuo","doi":"10.1093/jncics/pkag060","DOIUrl":"10.1093/jncics/pkag060","url":null,"abstract":"<p><strong>Background: </strong>Research suggests that burnout and work-related quality of life are concerns for pediatric oncology professionals, with limited supportive resources. This study aimed to address this resource gap through an intervention promoting hope and targeting burnout and quality of life in this group.</p><p><strong>Methods: </strong>A single-arm pilot study of the intervention was conducted at Rady Children's Hospital San Diego. The intervention was delivered as a single-session workshop, followed by reinforcement through a mobile application. Feasibility was assessed through recruitment and retention metrics, application usage data, and informal participant acceptability feedback. Exploratory efficacy analyses were conducted on measures of hope and perceived control (intervention mechanisms), occupational burnout and professional quality of life (primary outcomes), and empathy (secondary outcome) at baseline and 1, 4, and 12 weeks post-intervention.</p><p><strong>Results: </strong>Twenty participants were consented and 18 participated, with 13 (72%) completing 12-week surveys. A total of 15 participants (83%) opted to receive daily push notifications, but only 3 (20%) engaged in daily booster questions. Positive feedback suggested acceptability. Exploratory findings suggested changes in emotional exhaustion (baseline to 1 week, P = .02; baseline to 4 weeks, P = .01), a sub-construct of burnout, and secondary traumatic stress (baseline to 4 weeks, P = .01; baseline to 12-week scores, P = .01), a sub-construct of professional quality of life.</p><p><strong>Conclusions: </strong>The Hopetimize intervention was feasible for pediatric oncology health-care professionals, although daily application usage was limited. Exploratory findings suggested that a randomized controlled trial would be beneficial to delineate intervention effects on the proposed mechanisms and outcomes.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13340464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148225514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}